# Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

> **NCT06047184** · PHASE1 · UNKNOWN · sponsor: **BeBetter Med Inc** · enrollment: 106 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** BEBT-209 capsules
- **DRUG:** Letrozole tablets
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT06047184
- **Lead sponsor:** BeBetter Med Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-15
- **Primary completion:** 2023-10-20
- **Final completion:** 2023-11-20
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2023-09-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06047184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06047184, "Phase I Study of BEBT-209 in Women With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06047184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*